

CLAIMS

1. Use of a LINE-1 inhibitor in the manufacture of a medicament to enhance cognition, inhibit cognitive decline, treat or prevent a cognitive deficit disorder, or treat or prevent Creutzfeldt-Jakob disease (CJD) in a subject in need thereof, wherein the LINE-1 inhibitor is censavudine,



, or


.

2. The use of claim 1, wherein the LINE-1 inhibitor is to be administered to enhance cognition.

3. The use of claim 1, wherein the LINE-1 inhibitor is to be administered to inhibit cognitive decline.


4. The use of claim 1, wherein the LINE-1 inhibitor is to be administered to treat or prevent a cognitive deficit disorder.

5. The use of claim 4, wherein the cognitive deficit disorder is a learning disorder, a memory disorder, a sensory perception disorder, an attention deficit/hyperactivity disorder, associated with autism or Asperger's syndrome, mild cognitive impairment, age-related cognitive decline, associated with traumatic, tumor-related, or ischemic brain injury, a drug-related cognitive impairment, or an alcohol-related cognitive impairment.

6. The use of claim 1, wherein the LINE-1 inhibitor is to be administered to treat or prevent Creutzfeldt-Jakob disease (CJD).


7. The use of claim 1, wherein the LINE-1 inhibitor is censavudine.

8. The use of claim 1, wherein the LINE-1 inhibitor is:



.

9. The use of claim 1, wherein the LINE-1 inhibitor is:




.

10. The use of any one of claims 1-9, wherein the LINE-1 inhibitor is to be administered as a pharmaceutical composition comprising the LINE-1 inhibitor and pharmaceutically acceptable carrier.


11. The use of any one of claims 1-10, wherein one or more optional therapeutic agents are to be administered to the subject.

12. The use of any one of claims 1-11, wherein the subject is (a) not infected with the HIV virus, (b) is not suspected of being infected with the HIV virus, and/or (c) is not being treated to prevent infection with the HIV virus.

13. A kit comprising a LINE-1 inhibitor, or a pharmaceutical composition thereof, and instructions for administering the LINE-1 inhibitor, or pharmaceutical composition thereof, to enhance cognition, inhibit cognitive decline, treat or prevent a cognitive deficit disorder, or treat or prevent CJD in a subject in need thereof, wherein the LINE-1 inhibitor is censavudine,




, or



.


14. The kit of claim 12, wherein the LINE-1 inhibitor is censavudine.

15. The kit of claim 12, wherein the LINE-1 inhibitor is:



.

16. The kit of claim 12, wherein the LINE-1 inhibitor is:



.